Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.

Boned Del Río I, Young LC, Sari S, Jones GG, Ringham-Terry B, Hartig N, Rejnowicz E, Lei W, Bhamra A, Surinova S, Rodriguez-Viciana P.

Proc Natl Acad Sci U S A. 2019 Jul 2;116(27):13330-13339. doi: 10.1073/pnas.1902658116. Epub 2019 Jun 18.

2.

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.

Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, Areso Zubiaur I, El-Bahrawy MA, Hynds RE, Lei W, Molina-Arcas M, Downward J, Rodriguez-Viciana P.

Nat Commun. 2019 Jun 10;10(1):2532. doi: 10.1038/s41467-019-10367-x.

3.

SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.

Young LC, Hartig N, Boned Del Río I, Sari S, Ringham-Terry B, Wainwright JR, Jones GG, McCormick F, Rodriguez-Viciana P.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10576-E10585. doi: 10.1073/pnas.1720352115. Epub 2018 Oct 22.

4.

MRAS: A Close but Understudied Member of the RAS Family.

Young LC, Rodriguez-Viciana P.

Cold Spring Harb Perspect Med. 2018 Dec 3;8(12). pii: a033621. doi: 10.1101/cshperspect.a033621. Review.

PMID:
29311130
5.

An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth.

Young LC, Hartig N, Muñoz-Alegre M, Oses-Prieto JA, Durdu S, Bender S, Vijayakumar V, Vietri Rudan M, Gewinner C, Henderson S, Jathoul AP, Ghatrora R, Lythgoe MF, Burlingame AL, Rodriguez-Viciana P.

Mol Cell. 2013 Dec 12;52(5):679-92. doi: 10.1016/j.molcel.2013.10.004. Epub 2013 Nov 7.

6.

ERBB4 confers metastatic capacity in Ewing sarcoma.

Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FR, da Cunha IW, Rodriguez-Viciana P, Cheng H, Tavares Guerreiro Fregnani JH, Reynolds P, Arceci RJ, Nicholson A, Triche TJ, Soares FA, Flanagan AM, Wang YZ, Strauss SJ, Sorensen PH.

EMBO Mol Med. 2013 Jul;5(7):1087-102. doi: 10.1002/emmm.201202343. Epub 2013 May 16.

7.

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F.

Cancer Res. 2008 Oct 1;68(19):8127-36. doi: 10.1158/0008-5472.CAN-08-0755.

8.

Biochemical characterization of novel germline BRAF and MEK mutations in cardio-facio-cutaneous syndrome.

Rodriguez-Viciana P, Rauen KA.

Methods Enzymol. 2008;438:277-89. doi: 10.1016/S0076-6879(07)38019-1.

PMID:
18413255
9.

Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control.

Rodriguez-Viciana P, Collins C, Fried M.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19290-5. Epub 2006 Dec 8.

10.

mTOR-independent translational control of the extrinsic cell death pathway by RalA.

Panner A, Nakamura JL, Parsa AT, Rodriguez-Viciana P, Berger MS, Stokoe D, Pieper RO.

Mol Cell Biol. 2006 Oct;26(20):7345-57. Epub 2006 Aug 7.

11.

Cancer targets in the Ras pathway.

Rodriguez-Viciana P, Tetsu O, Oda K, Okada J, Rauen K, McCormick F.

Cold Spring Harb Symp Quant Biol. 2005;70:461-7. Review.

PMID:
16869784
12.

Characterization of interactions between ras family GTPases and their effectors.

Rodriguez-Viciana P, McCormick F.

Methods Enzymol. 2006;407:187-94.

PMID:
16757324
13.

A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity.

Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F.

Mol Cell. 2006 Apr 21;22(2):217-30.

14.

Ras ubiquitination: coupling spatial sorting and signal transmission.

Rodriguez-Viciana P, McCormick F.

Cancer Cell. 2006 Apr;9(4):243-4.

15.

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA.

Science. 2006 Mar 3;311(5765):1287-90. Epub 2006 Jan 26.

16.
17.

A conditional feedback loop regulates Ras activity through EphA2.

Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, Gray JW, McCormick F.

Cancer Cell. 2005 Aug;8(2):111-8.

18.

RalGDS comes of age.

Rodriguez-Viciana P, McCormick F.

Cancer Cell. 2005 Mar;7(3):205-6.

19.

Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate.

Rodriguez-Viciana P, Sabatier C, McCormick F.

Mol Cell Biol. 2004 Jun;24(11):4943-54.

20.

Ras activation of phosphatidylinositol 3-kinase and Akt.

Rodriguez-Viciana P, Downward J.

Methods Enzymol. 2001;333:37-44. No abstract available.

PMID:
11400352
21.

Induced expression of Rnd3 is associated with transformation of polarized epithelial cells by the Raf-MEK-extracellular signal-regulated kinase pathway.

Hansen SH, Zegers MM, Woodrow M, Rodriguez-Viciana P, Chardin P, Mostov KE, McMahon M.

Mol Cell Biol. 2000 Dec;20(24):9364-75.

22.

H-Ras activation promotes cytoplasmic accumulation and phosphoinositide 3-OH kinase association of beta-catenin in epidermal keratinocytes.

Espada J, Pérez-Moreno M, Braga VM, Rodriguez-Viciana P, Cano A.

J Cell Biol. 1999 Sep 6;146(5):967-80.

23.

Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase.

Jimenez C, Jones DR, Rodríguez-Viciana P, Gonzalez-García A, Leonardo E, Wennström S, von Kobbe C, Toran JL, R-Borlado L, Calvo V, Copin SG, Albar JP, Gaspar ML, Diez E, Marcos MA, Downward J, Martinez-A C, Mérida I, Carrera AC.

EMBO J. 1998 Feb 2;17(3):743-53.

24.

Interaction of Ras with phosphoinositide 3-kinase gamma.

Rubio I, Rodriguez-Viciana P, Downward J, Wetzker R.

Biochem J. 1997 Sep 15;326 ( Pt 3):891-5.

25.

Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway.

Khwaja A, Rodriguez-Viciana P, Wennström S, Warne PH, Downward J.

EMBO J. 1997 May 15;16(10):2783-93.

26.

Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras.

Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J.

Cell. 1997 May 2;89(3):457-67.

27.

Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB.

Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G.

Nature. 1997 Feb 6;385(6616):544-8.

PMID:
9020362
28.

R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways.

Marte BM, Rodriguez-Viciana P, Wennström S, Warne PH, Downward J.

Curr Biol. 1997 Jan 1;7(1):63-70. Erratum in: Curr Biol 1997 Mar 1;7(3):197.

29.

Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation.

Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD, Downward J.

EMBO J. 1996 May 15;15(10):2442-51.

30.

Phosphatidylinositol 3' kinase: one of the effectors of Ras.

Rodriguez-Viciana P, Marte BM, Warne PH, Downward J.

Philos Trans R Soc Lond B Biol Sci. 1996 Feb 29;351(1336):225-31; discussion 231-2. Review.

PMID:
8650270
31.

The activation of phosphatidylinositol 3-kinase by Ras.

Kodaki T, Woscholski R, Hallberg B, Rodriguez-Viciana P, Downward J, Parker PJ.

Curr Biol. 1994 Sep 1;4(9):798-806.

PMID:
7820549
32.

Phosphatidylinositol-3-OH kinase as a direct target of Ras.

Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J.

Nature. 1994 Aug 18;370(6490):527-32.

PMID:
8052307
33.

Supplemental Content

Loading ...
Support Center